Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 23;13(2):e1005345.
doi: 10.1371/journal.pcbi.1005345. eCollection 2017 Feb.

ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding

Affiliations

ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding

Alice R Walker et al. PLoS Comput Biol. .

Abstract

The search for prostate cancer biomarkers has received increased attention and several DNA repair related enzymes have been linked to this dysfunction. Here we report a targeted search for single nucleotide polymorphisms (SNPs) and functional impact characterization of human ALKBH family dioxygenases related to prostate cancer. Our results uncovered a SNP of ALKBH7, rs7540, which is associated with prostate cancer disease in a statistically significantly manner in two separate cohorts, and maintained in African American men. Comparisons of molecular dynamics (MD) simulations on the wild-type and variant protein structures indicate that the resulting alteration in the enzyme induces a significant structural change that reduces ALKBH7's ability to bind its cosubstrate. Experimental spectroscopy studies with purified proteins validate our MD predictions and corroborate the conclusion that this cancer-associated mutation affects productive cosubstrate binding in ALKBH7.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig 1
Fig 1. Structural and dynamic comparison between WT and R191Q ALKBH7 with bound α-kg.
a, Overlay of representative structures for WT (gray) and R191Q mutant (yellow) forms of ALKBH7. Active site residues and α-kg as well as the site undergoing substitution are displayed (licorice). b, 180 degree rotation and close-up of the substituted site. c, 90 degree rotation and close-up of the active site, with each relevant active site residue and α-kg labeled. Dashed lines in gray represent the original bonds to the metal ion in the crystal structure, and dashed lines in orange represent the new bonds to the metal ion near the end of the trajectory for the variant protein. d, Correlation difference for each residue in the WT protein with respect to the R191Q variant mapped onto the protein structure using the mutation site as the reference. e, Distance analysis for key residues in the SNP variant and active sites (with respect to their centers of mass) throughout the simulation trajectory.
Fig 2
Fig 2. Hydrogen bond analysis for the WT/R191Q variant with α-kg.
Residues colored in red denote amino acids involved in H-bonds for over 30% of the WT trajectory and broken for over 90% of the R191Q variant trajectory. Residues colored in orange are involved in hydrogen bonds for both trajectories, but are present for at least 30% less of the time in the variant trajectory. The hydrogen bonds between these residues are displayed in blue. The corresponding analysis for the WT/SNP variant with succinate are given in the Supplementary Information.
Fig 3
Fig 3. Average binding enthalpies for cosubstrate α-kg and Fe at the active site (in kcal/mol) for the simulation.
Results for the product (succinate) are reported in the Supplementary Information.
Fig 4
Fig 4. Difference absorption spectra of WT ALKBH7 and its R191Q variant.
The spectra of the anaerobic proteins (0.3 mM) were recorded in the presence of 2 mM α-kg and 100 μM Fe(II). The difference spectra were obtained by subtracting the spectra for proteins with α-kg, but without the metal. A, WT ALKBH7; B, R191Q ALKBH7.

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. 10.3322/caac.21254 - DOI - PubMed
    1. Rossiter BJ, Caskey CT. Presymptomatic testing for genetic diseases of later life. Pharmacoepidemiological considerations. Drugs Aging. 1995;7(2):117–130. - PubMed
    1. Peakall D, Shugart L. The Human Genome Project (HGP). Ecotoxicology. 2002;11(1):7. - PubMed
    1. Caskey CT. Using genetic diagnosis to determine individual therapeutic utility. Annu Rev Med. 2010;61:1–15. 10.1146/annurev-med-011209-132719 - DOI - PubMed
    1. Caskey CT. Presymptomatic diagnosis: a first step toward genetic health care. Science. 1993;262(5130):48–49. - PubMed

MeSH terms